Remarkably, JAK2 signaling is a particularly important driver in t(8;21)(q22;q22.1) AML as indicated by the presence of activating JAK2 mutations specifically in this but not other AML subtypes [47]. This evidence concerns the gene JAK2 and acute myeloid leukemia.